Compare KEN & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | LGND |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | 68 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2014 | N/A |
| Metric | KEN | LGND |
|---|---|---|
| Price | $65.90 | $315.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $256.29 |
| AVG Volume (30 Days) | 24.6K | ★ 487.4K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.25 |
| Revenue Next Year | N/A | $19.41 |
| P/E Ratio | ★ $9.21 | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.50 | $122.27 |
| 52 Week High | $95.93 | $326.63 |
| Indicator | KEN | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 67.37 |
| Support Level | $59.90 | $180.85 |
| Resistance Level | $70.74 | N/A |
| Average True Range (ATR) | 1.49 | 14.06 |
| MACD | 0.52 | 0.47 |
| Stochastic Oscillator | 10.15 | 81.98 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include: OPC Power Plants, which generates and supplies electricity and energy in Israel; and CPV Group, which generates and supplies electricity and energy in the United States. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.